{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T03:01:42Z","timestamp":1789354902696,"version":"build-2803163510"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002531","name":"Kyungpook National University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002531","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-026-01736-z","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T15:54:00Z","timestamp":1770306840000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic Potential of Tyrosine Kinase Inhibitors in Advanced Thyroid Cancer"],"prefix":"10.1007","volume":"28","author":[{"given":"Prakash","family":"Gangadaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidya","family":"Sankarapandian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raksa","family":"Arun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kandasamy Nagarajan","family":"ArulJothi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya Lakshmi","family":"Rajendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Min","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athesh","family":"Kumaraswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridharan","family":"Gurunagarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byeong-Cheol","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"1736_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s13193-021-01429-y","volume":"13","author":"JB Shank","year":"2022","unstructured":"Shank JB, Are C, Wenos CD. Thyroid cancer: global burden and trends. Indian J Surg Oncol. 2022;13:40\u20135. https:\/\/doi.org\/10.1007\/s13193-021-01429-y.","journal-title":"Indian J Surg Oncol"},{"key":"1736_CR2","unstructured":"Lee K, Anastasopoulou C, Chandran C, Cassaro S. Thyroid Cancer. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Aug 8]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459299\/. Accessed 8 Aug 2025."},{"key":"1736_CR3","doi-asserted-by":"publisher","first-page":"6251","DOI":"10.7150\/thno.57689","volume":"11","author":"JM Oh","year":"2021","unstructured":"Oh JM, Ahn B-C. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS. Theranostics. 2021;11:6251\u201377. https:\/\/doi.org\/10.7150\/thno.57689.","journal-title":"Theranostics"},{"key":"1736_CR4","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.3390\/curroncol31060252","volume":"31","author":"AS Harahap","year":"2024","unstructured":"Harahap AS, Roren RS, Imtiyaz S. A comprehensive review and insights into the new entity of differentiated high-grade thyroid carcinoma. Curr Oncol. 2024;31:3311\u201328. https:\/\/doi.org\/10.3390\/curroncol31060252.","journal-title":"Curr Oncol"},{"key":"1736_CR5","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1089\/thy.2019.0514","volume":"30","author":"ME Cabanillas","year":"2020","unstructured":"Cabanillas ME, Dadu R, Iyer P, Wanland KB, Busaidy NL, Ying A, et al. Acquired secondary RAS mutation in BRAFV600E-mutated thyroid cancer patients treated with BRAF inhibitors. Thyroid. 2020;30:1288\u201396. https:\/\/doi.org\/10.1089\/thy.2019.0514.","journal-title":"Thyroid"},{"key":"1736_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/s0304-3835(00)00697-2","volume":"163","author":"O Gimm","year":"2001","unstructured":"Gimm O. Thyroid cancer. Cancer Lett. 2001;163:143\u201356. https:\/\/doi.org\/10.1016\/s0304-3835(00)00697-2.","journal-title":"Cancer Lett"},{"key":"1736_CR7","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1016\/S0140-6736(16)30172-6","volume":"388","author":"ME Cabanillas","year":"2016","unstructured":"Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet Lond Engl. 2016;388:2783\u201395. https:\/\/doi.org\/10.1016\/S0140-6736(16)30172-6.","journal-title":"Lancet Lond Engl"},{"key":"1736_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S2213-8587(21)00027-9","volume":"9","author":"A Miranda-Filho","year":"2021","unstructured":"Miranda-Filho A, Lortet-Tieulent J, Bray F, Cao B, Franceschi S, Vaccarella S, et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 2021;9:225\u201334. https:\/\/doi.org\/10.1016\/S2213-8587(21)00027-9.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1736_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1736_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1146\/annurev-med-061512-105739","volume":"65","author":"T Carling","year":"2014","unstructured":"Carling T, Udelsman R. Thyroid cancer. Annu Rev Med. 2014;65:125\u201337. https:\/\/doi.org\/10.1146\/annurev-med-061512-105739.","journal-title":"Annu Rev Med"},{"key":"1736_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/cac2.12416","volume":"43","author":"A Goenka","year":"2023","unstructured":"Goenka A, Khan F, Verma B, Sinha P, Dmello CC, Jogalekar MP, et al. Tumor microenvironment signaling and therapeutics in cancer progression. Cancer Commun. 2023;43:525\u201361. https:\/\/doi.org\/10.1002\/cac2.12416.","journal-title":"Cancer Commun"},{"key":"1736_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000003352","author":"K Chakraborty","year":"2025","unstructured":"Chakraborty K, Rajendran RL, Kothiwal S, Majhi S, Dey A, Ghosh S, et al. Cancer-associated fibroblasts as a potential therapeutic target for thyroid cancers. Int J Surg Lond Engl. 2025. https:\/\/doi.org\/10.1097\/JS9.0000000000003352.","journal-title":"Int J Surg Lond Engl"},{"key":"1736_CR13","doi-asserted-by":"publisher","first-page":"026","DOI":"10.17352\/ijcem.000040","volume":"5","author":"A Jayarangaiah","year":"2019","unstructured":"Jayarangaiah A, Sidhu G, Brown J, Barrett-Campbell O, Bahtiyar G, Youssef I, et al. Therapeutic options for advanced thyroid cancer. Int J Clin Endocrinol Metab. 2019;5:026\u201334. https:\/\/doi.org\/10.17352\/ijcem.000040.","journal-title":"Int J Clin Endocrinol Metab"},{"key":"1736_CR14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2967\/jnumed.121.262402","volume":"63","author":"AM Avram","year":"2022","unstructured":"Avram AM, Zukotynski K, Nadel HR, Giovanella L. Management of differentiated thyroid cancer: the standard of care. J Nucl Med Off Publ Soc Nucl Med. 2022;63:189\u201395. https:\/\/doi.org\/10.2967\/jnumed.121.262402.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"1736_CR15","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_389708","volume":"43","author":"S Agosto Salgado","year":"2023","unstructured":"Agosto Salgado S, Kaye ER, Sargi Z, Chung CH, Papaleontiou M. Management of advanced thyroid cancer: overview, advances, and opportunities. Am Soc Clin Oncol Educ Book. 2023;43:e389708. https:\/\/doi.org\/10.1200\/EDBK_389708.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1736_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cells14141087","volume":"14","author":"K Prakash","year":"2025","unstructured":"Prakash K, Rajendran RL, Dhayalan S, Gangadaran P, Ahn B-C, Aruljothi KN. Natural killer cell and extracellular vesicle-based immunotherapy in thyroid cancer: advances, challenges, and future perspectives. Cells. 2025;14:1087. https:\/\/doi.org\/10.3390\/cells14141087.","journal-title":"Cells"},{"key":"1736_CR17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.semcancer.2020.11.013","volume":"79","author":"P Fallahi","year":"2022","unstructured":"Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, et al. Molecular targets of tyrosine kinase inhibitors in thyroid cancer. Semin Cancer Biol. 2022;79:180\u201396. https:\/\/doi.org\/10.1016\/j.semcancer.2020.11.013.","journal-title":"Semin Cancer Biol"},{"key":"1736_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.surg.2016.04.053","volume":"161","author":"RW Randle","year":"2017","unstructured":"Randle RW, Balentine CJ, Leverson GE, Havlena JA, Sippel RS, Schneider DF, et al. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery. 2017;161:137\u201346. https:\/\/doi.org\/10.1016\/j.surg.2016.04.053.","journal-title":"Surgery"},{"key":"1736_CR19","unstructured":"Ramos Santillan V, Master SR, Menon G, Burns B. Medullary Thyroid Cancer. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Oct 20]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459354\/. Accessed 20 Oct 2025."},{"key":"1736_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082104","volume":"12","author":"M Al-Jundi","year":"2020","unstructured":"Al-Jundi M, Thakur S, Gubbi S, Klubo-Gwiezdzinska J. Novel targeted therapies for metastatic thyroid cancer-a comprehensive review. Cancers. 2020;12:2104. https:\/\/doi.org\/10.3390\/cancers12082104.","journal-title":"Cancers"},{"key":"1736_CR21","first-page":"1454","volume":"63","author":"ET Kimura","year":"2003","unstructured":"Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET\/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454\u20137.","journal-title":"Cancer Res"},{"key":"1736_CR22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/01.pas.0000176432.73455.1b","volume":"30","author":"AJ Adeniran","year":"2006","unstructured":"Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006;30:216\u201322. https:\/\/doi.org\/10.1097\/01.pas.0000176432.73455.1b.","journal-title":"Am J Surg Pathol"},{"key":"1736_CR23","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMc1613118","volume":"375","author":"JA Fagin","year":"2016","unstructured":"Fagin JA, Wells SA. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016;375:2307. https:\/\/doi.org\/10.1056\/NEJMc1613118.","journal-title":"N Engl J Med"},{"key":"1736_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/sj.cr.7290105","volume":"12","author":"W Zhang","year":"2002","unstructured":"Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002;12:9\u201318. https:\/\/doi.org\/10.1038\/sj.cr.7290105.","journal-title":"Cell Res"},{"key":"1736_CR25","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-25-0057","volume":"14","author":"AH Karimi","year":"2025","unstructured":"Karimi AH, Zeng PY, Cecchini M, Barrett JW, Pan H, Ying S, et al. NOVEL INSIGHTS IN ADVANCED THYROID CARCINOMA: FROM MECHANISMS TO TREATMENTS: Molecular insights into the origin, biology, and treatment of anaplastic thyroid carcinoma. Eur Thyroid J. 2025;14:e250057. https:\/\/doi.org\/10.1530\/ETJ-25-0057.","journal-title":"Eur Thyroid J"},{"key":"1736_CR26","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.1038\/sj.onc.1206706","volume":"22","author":"P Soares","year":"2003","unstructured":"Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, et al. BRAF mutations and RET\/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003;22:4578\u201380. https:\/\/doi.org\/10.1038\/sj.onc.1206706.","journal-title":"Oncogene"},{"key":"1736_CR27","doi-asserted-by":"publisher","first-page":"7436","DOI":"10.1038\/sj.onc.1207980","volume":"23","author":"M Frattini","year":"2004","unstructured":"Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene. 2004;23:7436\u201340. https:\/\/doi.org\/10.1038\/sj.onc.1207980.","journal-title":"Oncogene"},{"key":"1736_CR28","doi-asserted-by":"publisher","first-page":"R43","DOI":"10.1530\/JOE-17-0266","volume":"235","author":"MA Zaballos","year":"2017","unstructured":"Zaballos MA, Santisteban P. Key signaling pathways in thyroid cancer. J Endocrinol. 2017;235:R43\u201361. https:\/\/doi.org\/10.1530\/JOE-17-0266.","journal-title":"J Endocrinol"},{"key":"1736_CR29","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1530\/EJE-09-0353","volume":"161","author":"MC Zatelli","year":"2009","unstructured":"Zatelli MC, Trasforini G, Leoni S, Frigato G, Buratto M, Tagliati F, et al. BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol. 2009;161:467\u201373. https:\/\/doi.org\/10.1530\/EJE-09-0353.","journal-title":"Eur J Endocrinol"},{"key":"1736_CR30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12022-009-9073-3","volume":"20","author":"S Chiosea","year":"2009","unstructured":"Chiosea S, Nikiforova M, Zuo H, Ogilvie J, Gandhi M, Seethala RR, et al. A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma. Endocr Pathol. 2009;20:122\u20136. https:\/\/doi.org\/10.1007\/s12022-009-9073-3.","journal-title":"Endocr Pathol"},{"key":"1736_CR31","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1001\/jama.2013.3620","volume":"309","author":"AR Cappola","year":"2013","unstructured":"Cappola AR, Mandel SJ. Molecular testing in thyroid cancer: BRAF mutation status and mortality. JAMA. 2013;309:1529\u201330. https:\/\/doi.org\/10.1001\/jama.2013.3620.","journal-title":"JAMA"},{"key":"1736_CR32","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1210\/jc.2016-1775","volume":"101","author":"L Torregrossa","year":"2016","unstructured":"Torregrossa L, Viola D, Sensi E, Giordano M, Piaggi P, Romei C, et al. Papillary Thyroid Carcinoma With Rare Exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience. J Clin Endocrinol Metab. 2016;101:4413\u201320. https:\/\/doi.org\/10.1210\/jc.2016-1775.","journal-title":"J Clin Endocrinol Metab"},{"key":"1736_CR33","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1093\/jnci\/djp354","volume":"101","author":"G Pellegriti","year":"2009","unstructured":"Pellegriti G, De Vathaire F, Scollo C, Attard M, Giordano C, Arena S, et al. Papillary Thyroid Cancer Incidence in the Volcanic Area of Sicily. JNCI J Natl Cancer Inst. 2009;101:1575\u201383. https:\/\/doi.org\/10.1093\/jnci\/djp354.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"1736_CR34","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrc3431","volume":"13","author":"M Xing","year":"2013","unstructured":"Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13:184\u201399. https:\/\/doi.org\/10.1038\/nrc3431.","journal-title":"Nat Rev Cancer"},{"key":"1736_CR35","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","volume":"159","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676\u201390. https:\/\/doi.org\/10.1016\/j.cell.2014.09.050.","journal-title":"Cell"},{"issue":"Suppl 2","key":"1736_CR36","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1038\/modpathol.2008.10","volume":"21","author":"YE Nikiforov","year":"2008","unstructured":"Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol Off J US Can Acad Pathol Inc. 2008;21(Suppl 2):S37-43. https:\/\/doi.org\/10.1038\/modpathol.2008.10.","journal-title":"Mod Pathol Off J US Can Acad Pathol Inc"},{"key":"1736_CR37","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.3390\/ijms22041950","volume":"22","author":"J Hu","year":"2021","unstructured":"Hu J, Yuan IJ, Mirshahidi S, Simental A, Lee SC, Yuan X. Thyroid carcinoma: phenotypic features, underlying biology and potential relevance for targeting therapy. Int J Mol Sci. 2021;22:1950. https:\/\/doi.org\/10.3390\/ijms22041950.","journal-title":"Int J Mol Sci"},{"key":"1736_CR38","first-page":"6105","volume":"61","author":"MD Ringel","year":"2001","unstructured":"Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res. 2001;61:6105\u201311.","journal-title":"Cancer Res"},{"key":"1736_CR39","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489\u2013501. https:\/\/doi.org\/10.1038\/nrc839.","journal-title":"Nat Rev Cancer"},{"key":"1736_CR40","doi-asserted-by":"publisher","first-page":"E1139","DOI":"10.1210\/jc.2011-2748","volume":"97","author":"A Faustino","year":"2012","unstructured":"Faustino A, Couto JP, P\u00f3pulo H, Rocha AS, Pardal F, Cameselle-Teijeiro JM, et al. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012;97:E1139\u20131149. https:\/\/doi.org\/10.1210\/jc.2011-2748.","journal-title":"J Clin Endocrinol Metab"},{"key":"1736_CR41","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1158\/1078-0432.CCR-11-2700","volume":"18","author":"A Tamburrino","year":"2012","unstructured":"Tamburrino A, Molinolo AA, Salerno P, Chernock RD, Raffeld M, Xi L, et al. Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. Clin Cancer Res. 2012;18:3532\u201340. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-2700.","journal-title":"Clin Cancer Res"},{"key":"1736_CR42","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1136\/jmg.2004.018036","volume":"41","author":"R Pilarski","year":"2004","unstructured":"Pilarski R, Eng C. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet. 2004;41:323\u20136. https:\/\/doi.org\/10.1136\/jmg.2004.018036.","journal-title":"J Med Genet"},{"key":"1736_CR43","first-page":"2039","volume":"11","author":"SM Myers","year":"1995","unstructured":"Myers SM, Eng C, Ponder BA, Mulligan LM. Characterization of RET proto-oncogene 3\u2019 splicing variants and polyadenylation sites: a novel C-terminus for RET. Oncogene. 1995;11:2039\u201345.","journal-title":"Oncogene"},{"key":"1736_CR44","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/0092-8674(90)90659-3","volume":"60","author":"M Grieco","year":"1990","unstructured":"Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 1990;60:557\u201363. https:\/\/doi.org\/10.1016\/0092-8674(90)90659-3.","journal-title":"Cell"},{"key":"1736_CR45","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1210\/en.2006-0921","volume":"148","author":"R Ciampi","year":"2007","unstructured":"Ciampi R, Nikiforov YE. RET\/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology. 2007;148:936\u201341. https:\/\/doi.org\/10.1210\/en.2006-0921.","journal-title":"Endocrinology"},{"key":"1736_CR46","first-page":"509","volume":"9","author":"M Santoro","year":"1994","unstructured":"Santoro M, Dathan NA, Berlingieri MT, Bongarzone I, Paulin C, Grieco M, et al. Molecular characterization of RET\/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene. 1994;9:509\u201316.","journal-title":"Oncogene"},{"key":"1736_CR47","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nrendo.2016.11","volume":"12","author":"C Romei","year":"2016","unstructured":"Romei C, Ciampi R, Elisei R. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nat Rev Endocrinol. 2016;12:192\u2013202. https:\/\/doi.org\/10.1038\/nrendo.2016.11.","journal-title":"Nat Rev Endocrinol"},{"key":"1736_CR48","doi-asserted-by":"publisher","first-page":"viii5","DOI":"10.1093\/annonc\/mdz383","volume":"30","author":"A Amatu","year":"2019","unstructured":"Amatu A, Sartore-Bianchi A, Bencardino K, Pizzutilo EG, Tosi F, Siena S. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. Ann Oncol. 2019;30:viii5-15. https:\/\/doi.org\/10.1093\/annonc\/mdz383.","journal-title":"Ann Oncol"},{"key":"1736_CR49","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.37765\/ajmc.2022.88834","volume":"28","author":"S Kummar","year":"2022","unstructured":"Kummar S, Italiano A, Brose MS, Carlson JJ, Sullivan SD, Lassen U, et al. Diagnosis and management of TRK fusion cancer. Am J Manag Care. 2022;28:S15\u201325. https:\/\/doi.org\/10.37765\/ajmc.2022.88834.","journal-title":"Am J Manag Care"},{"key":"1736_CR50","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","volume":"15","author":"E Cocco","year":"2018","unstructured":"Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15:731\u201347. https:\/\/doi.org\/10.1038\/s41571-018-0113-0.","journal-title":"Nat Rev Clin Oncol"},{"key":"1736_CR51","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/319743a0","volume":"319","author":"D Martin-Zanca","year":"1986","unstructured":"Martin-Zanca D, Hughes SH, Barbacid M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature. 1986;319:743\u20138. https:\/\/doi.org\/10.1038\/319743a0.","journal-title":"Nature"},{"key":"1736_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.103957","volume":"184","author":"Y Ma","year":"2023","unstructured":"Ma Y, Zhang Q, Zhang K, Liang Y, Ren F, Zhang J, et al. NTRK fusions in thyroid cancer: pathology and clinical aspects. Crit Rev Oncol Hematol. 2023;184:103957. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.103957.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1736_CR53","first-page":"1457","volume":"4","author":"I Bongarzone","year":"1989","unstructured":"Bongarzone I, Pierotti MA, Monzini N, Mondellini P, Manenti G, Donghi R, et al. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene. 1989;4:1457\u201362.","journal-title":"Oncogene"},{"key":"1736_CR54","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1158\/1078-0432.CCR-19-3165","volume":"26","author":"EY Rosen","year":"2020","unstructured":"Rosen EY, Goldman DA, Hechtman JF, Benayed R, Schram AM, Cocco E, et al. TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations. Clin Cancer Res. 2020;26:1624\u201332. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3165.","journal-title":"Clin Cancer Res"},{"key":"1736_CR55","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41379-019-0324-7","volume":"33","author":"JP Solomon","year":"2020","unstructured":"Solomon JP, Linkov I, Rosado A, Mullaney K, Rosen EY, Frosina D, et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2020;33:38\u201346. https:\/\/doi.org\/10.1038\/s41379-019-0324-7.","journal-title":"Mod Pathol"},{"key":"1736_CR56","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-21-0061","volume":"11","author":"M Eszlinger","year":"2022","unstructured":"Eszlinger M, Stewardson P, McIntyre JB, Box A, Khalil M, Hyrcza M, et al. Systematic population-based identification of NTRK and RET fusion-positive thyroid cancers. Eur Thyroid J. 2022;11:e210061. https:\/\/doi.org\/10.1530\/ETJ-21-0061.","journal-title":"Eur Thyroid J"},{"key":"1736_CR57","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1530\/EJE-20-1345","volume":"184","author":"Y Kong","year":"2021","unstructured":"Kong Y, Bu R, Parvathareddy SK, Siraj AK, Siraj N, Al-Sobhi SS, et al. NTRK fusion analysis reveals enrichment in Middle Eastern BRAF wild-type PTC. Eur J Endocrinol. 2021;184:503\u201311. https:\/\/doi.org\/10.1530\/EJE-20-1345.","journal-title":"Eur J Endocrinol"},{"key":"1736_CR58","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrg1656","volume":"6","author":"MA Blasco","year":"2005","unstructured":"Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet. 2005;6:611\u201322. https:\/\/doi.org\/10.1038\/nrg1656.","journal-title":"Nat Rev Genet"},{"key":"1736_CR59","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0014-5793(04)00356-4","volume":"564","author":"R Janknecht","year":"2004","unstructured":"Janknecht R. On the road to immortality: hTERT upregulation in cancer cells. FEBS Lett. 2004;564:9\u201313. https:\/\/doi.org\/10.1016\/S0014-5793(04)00356-4.","journal-title":"FEBS Lett"},{"key":"1736_CR60","doi-asserted-by":"publisher","first-page":"E1130","DOI":"10.1210\/jc.2013-4048","volume":"99","author":"X Liu","year":"2014","unstructured":"Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, et al. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab. 2014;99:E1130\u20131136. https:\/\/doi.org\/10.1210\/jc.2013-4048.","journal-title":"J Clin Endocrinol Metab"},{"key":"1736_CR61","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.1230062","volume":"339","author":"S Horn","year":"2013","unstructured":"Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339:959\u201361. https:\/\/doi.org\/10.1126\/science.1230062.","journal-title":"Science"},{"key":"1736_CR62","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1242\/dev.145615","volume":"144","author":"M Nilsson","year":"2017","unstructured":"Nilsson M, Fagman H. Development of the thyroid gland. Dev Camb Engl. 2017;144:2123\u201340. https:\/\/doi.org\/10.1242\/dev.145615.","journal-title":"Dev Camb Engl"},{"key":"1736_CR63","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/s0960-9822(01)00225-1","volume":"11","author":"L Patel","year":"2001","unstructured":"Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol. 2001;11:764\u20138. https:\/\/doi.org\/10.1016\/s0960-9822(01)00225-1.","journal-title":"Curr Biol"},{"key":"1736_CR64","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrendo.2014.115","volume":"10","author":"P Raman","year":"2014","unstructured":"Raman P, Koenig RJ. Pax-8-PPAR-\u03b3 fusion protein in thyroid carcinoma. Nat Rev Endocrinol. 2014;10:616\u201323. https:\/\/doi.org\/10.1038\/nrendo.2014.115.","journal-title":"Nat Rev Endocrinol"},{"key":"1736_CR65","first-page":"1690","volume":"57","author":"YE Nikiforov","year":"1997","unstructured":"Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA. Distinct pattern of Ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997;57:1690\u20134.","journal-title":"Cancer Res"},{"key":"1736_CR66","unstructured":"Thomson RJ, Moshirfar M, Ronquillo Y. Tyrosine Kinase Inhibitors. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Oct 21]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK563322\/. Accessed 21 Oct 2025."},{"key":"1736_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0801-5","volume":"17","author":"Q Jiao","year":"2018","unstructured":"Jiao Q, Bi L, Ren Y, Song S, Wang Q, Wang Y-S. Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer. 2018;17:36. https:\/\/doi.org\/10.1186\/s12943-018-0801-5.","journal-title":"Mol Cancer"},{"key":"1736_CR68","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1042\/bj20082234","volume":"418","author":"KI Patterson","year":"2009","unstructured":"Patterson KI, Brummer T, O\u2019Brien PM, Daly RJ. Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J. 2009;418:475\u201389. https:\/\/doi.org\/10.1042\/bj20082234.","journal-title":"Biochem J"},{"key":"1736_CR69","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1517\/17460441.2014.865012","volume":"9","author":"A Z\u00e1me\u010dn\u00edkova","year":"2014","unstructured":"Z\u00e1me\u010dn\u00edkova A. Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer. Expert Opin Drug Discov. 2014;9:77\u201392. https:\/\/doi.org\/10.1517\/17460441.2014.865012.","journal-title":"Expert Opin Drug Discov"},{"key":"1736_CR70","doi-asserted-by":"publisher","first-page":"F217","DOI":"10.1016\/s0304-419x(97)00022-x","volume":"1333","author":"KS Kolibaba","year":"1997","unstructured":"Kolibaba KS, Druker BJ. Protein tyrosine kinases and cancer. Biochim Biophys Acta. 1997;1333:F217\u2013248. https:\/\/doi.org\/10.1016\/s0304-419x(97)00022-x.","journal-title":"Biochim Biophys Acta"},{"key":"1736_CR71","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1677\/ERC-08-0304","volume":"17","author":"C Rodr\u00edguez-Antona","year":"2010","unstructured":"Rodr\u00edguez-Antona C, Pallares J, Montero-Conde C, Inglada-P\u00e9rez L, Castelblanco E, Landa I, et al. Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocr Relat Cancer. 2010;17:7\u201316. https:\/\/doi.org\/10.1677\/ERC-08-0304.","journal-title":"Endocr Relat Cancer"},{"key":"1736_CR72","first-page":"1029","volume":"146","author":"HF Dvorak","year":"1995","unstructured":"Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor\/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029\u201339.","journal-title":"Am J Pathol"},{"key":"1736_CR73","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/483439","volume":"2012","author":"KE Johnson","year":"2012","unstructured":"Johnson KE, Wilgus TA. Multiple roles for VEGF in non-melanoma skin cancer: angiogenesis and beyond. J Skin Cancer. 2012;2012:483439. https:\/\/doi.org\/10.1155\/2012\/483439.","journal-title":"J Skin Cancer"},{"key":"1736_CR74","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nrc3627","volume":"13","author":"HL Goel","year":"2013","unstructured":"Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013;13:871\u201382. https:\/\/doi.org\/10.1038\/nrc3627.","journal-title":"Nat Rev Cancer"},{"key":"1736_CR75","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00280-018-3657-x","volume":"82","author":"H Yamazaki","year":"2018","unstructured":"Yamazaki H, Yokose T, Hayashi H, Iwasaki H, Osanai S, Suganuma N, et al. Expression of vascular endothelial growth factor receptor 2 and clinical response to lenvatinib in patients with anaplastic thyroid cancer. Cancer Chemother Pharmacol. 2018;82:649\u201354. https:\/\/doi.org\/10.1007\/s00280-018-3657-x.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1736_CR76","first-page":"1006","volume":"52","author":"A Chaudhry","year":"1992","unstructured":"Chaudhry A, Papanicolaou V, Oberg K, Heldin CH, Funa K. Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res. 1992;52:1006\u201312.","journal-title":"Cancer Res"},{"key":"1736_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/1755-1536-6-10","volume":"6","author":"J Donovan","year":"2013","unstructured":"Donovan J, Shiwen X, Norman J, Abraham D. Platelet-derived growth factor alpha and beta receptors have overlapping functional activities towards fibroblasts. Fibrogenesis Tissue Repair. 2013;6:10. https:\/\/doi.org\/10.1186\/1755-1536-6-10.","journal-title":"Fibrogenesis Tissue Repair"},{"key":"1736_CR78","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1016\/j.bbapap.2012.10.015","volume":"1834","author":"P-H Chen","year":"2013","unstructured":"Chen P-H, Chen X, He X. Platelet-derived growth factors and their receptors: structural and functional perspectives. Biochim Biophys Acta. 2013;1834:2176\u201386. https:\/\/doi.org\/10.1016\/j.bbapap.2012.10.015.","journal-title":"Biochim Biophys Acta"},{"key":"1736_CR79","doi-asserted-by":"publisher","first-page":"9961","DOI":"10.18632\/oncotarget.14283","volume":"8","author":"J Chen","year":"2016","unstructured":"Chen J, Yuan W, Wu L, Tang Q, Xia Q, Ji J, et al. PDGF-D promotes cell growth, aggressiveness, angiogenesis and EMT transformation of colorectal cancer by activation of Notch1\/Twist1 pathway. Oncotarget. 2016;8:9961\u201373. https:\/\/doi.org\/10.18632\/oncotarget.14283.","journal-title":"Oncotarget"},{"key":"1736_CR80","doi-asserted-by":"publisher","first-page":"551","DOI":"10.4062\/biomolther.2020.205","volume":"29","author":"C-L Lin","year":"2021","unstructured":"Lin C-L, Tsai M-L, Chen Y, Liu W-N, Lin C-Y, Hsu K-W, et al. Platelet-derived growth factor receptor-\u03b1 subunit targeting suppresses metastasis in advanced thyroid cancer in vitro and in vivo. Biomol Ther (Seoul). 2021;29:551\u201361. https:\/\/doi.org\/10.4062\/biomolther.2020.205.","journal-title":"Biomol Ther (Seoul)"},{"key":"1736_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030366","volume":"11","author":"T Le","year":"2019","unstructured":"Le T, Gerber DE. Newer-generation EGFR inhibitors in lung cancer: how are they best used? Cancers. 2019;11:366. https:\/\/doi.org\/10.3390\/cancers11030366.","journal-title":"Cancers"},{"key":"1736_CR82","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1089\/thy.2011.0172","volume":"21","author":"M Landriscina","year":"2011","unstructured":"Landriscina M, Pannone G, Piscazzi A, Toti P, Fabiano A, Tortorella S, et al. Epidermal growth factor receptor 1 expression is upregulated in undifferentiated thyroid carcinomas in humans. Thyroid. 2011;21:1227\u201334. https:\/\/doi.org\/10.1089\/thy.2011.0172.","journal-title":"Thyroid"},{"key":"1736_CR83","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jss.2013.05.003","volume":"185","author":"KE Fisher","year":"2013","unstructured":"Fisher KE, Jani JC, Fisher SB, Foulks C, Hill CE, Weber CJ, et al. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma. J Surg Res. 2013;185:217\u201324. https:\/\/doi.org\/10.1016\/j.jss.2013.05.003.","journal-title":"J Surg Res"},{"key":"1736_CR84","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","volume":"13","author":"ME Lacouture","year":"2008","unstructured":"Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008;13:1001\u201311. https:\/\/doi.org\/10.1634\/theoncologist.2008-0131.","journal-title":"Oncologist"},{"key":"1736_CR85","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1210\/er.2019-00007","volume":"40","author":"ME Cabanillas","year":"2019","unstructured":"Cabanillas ME, Ryder M, Jimenez C. Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr Rev. 2019;40:1573\u2013604. https:\/\/doi.org\/10.1210\/er.2019-00007.","journal-title":"Endocr Rev"},{"key":"1736_CR86","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jfma.2020.04.021","volume":"120","author":"C-Y Lin","year":"2021","unstructured":"Lin C-Y, Chang JS, Huang S-M, Hung C-J, Hung C-L, Chang C-T, et al. Experience of sorafenib treatment in differentiated thyroid cancer from Taiwan. J Formos Med Assoc. 2021;120:189\u201395. https:\/\/doi.org\/10.1016\/j.jfma.2020.04.021.","journal-title":"J Formos Med Assoc"},{"key":"1736_CR87","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2147\/DDDT.S82972","volume":"10","author":"F Pitoia","year":"2016","unstructured":"Pitoia F, Jerkovich F. Selective use of Sorafenib in the treatment of thyroid cancer. Drug Des Devel Ther. 2016;10:1119\u201331. https:\/\/doi.org\/10.2147\/DDDT.S82972.","journal-title":"Drug Des Devel Ther"},{"key":"1736_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/2045-824X-6-18","volume":"6","author":"Y Yamamoto","year":"2014","unstructured":"Yamamoto Y, Matsui J, Matsushima T, Obaishi H, Miyazaki K, Nakamura K, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6:18. https:\/\/doi.org\/10.1186\/2045-824X-6-18.","journal-title":"Vasc Cell"},{"key":"1736_CR89","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2147\/CMAR.S348711","volume":"15","author":"L Roof","year":"2023","unstructured":"Roof L, Geiger JL. Clinical utility of Cabozantinib in the treatment of locally advanced or metastatic differentiated thyroid carcinoma: patient selection and reported outcomes. Cancer Manag Res. 2023;15:343\u201350. https:\/\/doi.org\/10.2147\/CMAR.S348711.","journal-title":"Cancer Manag Res"},{"key":"1736_CR90","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1200\/JCO.2010.32.4145","volume":"29","author":"R Kurzrock","year":"2011","unstructured":"Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011;29:2660\u20136. https:\/\/doi.org\/10.1200\/JCO.2010.32.4145.","journal-title":"J Clin Oncol"},{"key":"1736_CR91","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.2147\/DDDT.S72495","volume":"9","author":"P Fallahi","year":"2015","unstructured":"Fallahi P, Di Bari F, Ferrari SM, Spisni R, Materazzi G, Miccoli P, et al. Selective use of Vandetanib in the treatment of thyroid cancer. Drug Des Devel Ther. 2015;9:3459\u201370. https:\/\/doi.org\/10.2147\/DDDT.S72495.","journal-title":"Drug Des Devel Ther"},{"key":"1736_CR92","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3803\/EnM.2020.687","volume":"35","author":"M Kim","year":"2020","unstructured":"Kim M, Yoon JH, Ahn J, Jeon MJ, Kim HK, Lim DJ, et al. Vandetanib for the management of advanced medullary thyroid cancer: a real-world multicenter experience. Endocrinol Metab. 2020;35:587\u201394. https:\/\/doi.org\/10.3803\/EnM.2020.687.","journal-title":"Endocrinol Metab"},{"key":"1736_CR93","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","volume":"30","author":"SA Wells","year":"2012","unstructured":"Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30:134\u201341. https:\/\/doi.org\/10.1200\/JCO.2011.35.5040.","journal-title":"J Clin Oncol"},{"key":"1736_CR94","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae158","volume":"8","author":"O Elghawy","year":"2024","unstructured":"Elghawy O, Barsouk A, Heidlauf A, Chen S, Cohen RB, Sun L. Single-institution experience of larotrectinib therapy for patients with NTRK fusion-positive thyroid carcinoma. J Endocr Soc. 2024;8:bvae158. https:\/\/doi.org\/10.1210\/jendso\/bvae158.","journal-title":"J Endocr Soc"},{"key":"1736_CR95","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1530\/EJE-21-1259","volume":"186","author":"SG Waguespack","year":"2022","unstructured":"Waguespack SG, Drilon A, Lin JJ, Brose MS, McDermott R, Almubarak M, et al. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol. 2022;186:631\u201343. https:\/\/doi.org\/10.1530\/EJE-21-1259.","journal-title":"Eur J Endocrinol"},{"key":"1736_CR96","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials. Lancet Oncol. 2020;21:271\u201382. https:\/\/doi.org\/10.1016\/S1470-2045(19)30691-6.","journal-title":"Lancet Oncol"},{"key":"1736_CR97","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","volume":"28","author":"GD Demetri","year":"2022","unstructured":"Demetri GD, De Braud F, Drilon A, Siena S, Patel MR, Cho BC, et al. Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors. Clin Cancer Res. 2022;28:1302\u201312. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3597.","journal-title":"Clin Cancer Res"},{"key":"1736_CR98","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","volume":"29","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Velcheti V, Tuch BB, Ebata K, Busaidy NL, Cabanillas ME, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29:1869\u201376. https:\/\/doi.org\/10.1093\/annonc\/mdy137.","journal-title":"Ann Oncol"},{"key":"1736_CR99","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1210\/clinem\/dgac325","volume":"107","author":"R Elisei","year":"2022","unstructured":"Elisei R, Ciampi R, Matrone A, Prete A, Gambale C, Ramone T, et al. Somatic RET indels in sporadic medullary thyroid cancer: prevalence and response to selpercatinib. J Clin Endocrinol Metab. 2022;107:2195\u2013202. https:\/\/doi.org\/10.1210\/clinem\/dgac325.","journal-title":"J Clin Endocrinol Metab"},{"key":"1736_CR100","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1200\/JCO.2012.43.5966","volume":"31","author":"KB Kim","year":"2013","unstructured":"Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, et al. Phase II study of the MEK1\/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013;31:482\u20139. https:\/\/doi.org\/10.1200\/JCO.2012.43.5966.","journal-title":"J Clin Oncol"},{"key":"1736_CR101","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022;33:406\u201315. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.014.","journal-title":"Ann Oncol"},{"key":"1736_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01899-w","volume":"9","author":"C Tomuleasa","year":"2024","unstructured":"Tomuleasa C, Tigu A-B, Munteanu R, Moldovan C-S, Kegyes D, Onaciu A, et al. Therapeutic advances of targeting receptor tyrosine kinases in cancer. Signal Transduct Target Ther. 2024;9:201. https:\/\/doi.org\/10.1038\/s41392-024-01899-w.","journal-title":"Signal Transduct Target Ther"},{"key":"1736_CR103","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.694","volume":"5","author":"X Ou","year":"2024","unstructured":"Ou X, Gao G, Habaz IA, Wang Y. Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies. MedComm. 2024;5:e694. https:\/\/doi.org\/10.1002\/mco2.694.","journal-title":"MedComm"},{"key":"1736_CR104","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1089\/thy.2022.0704","volume":"33","author":"ML Gild","year":"2023","unstructured":"Gild ML, Bullock M, Tsang V, Clifton-Bligh RJ, Robinson BG, Wirth LJ. Challenges and strategies to combat resistance mechanisms in thyroid cancer therapeutics. Thyroid Off J Am Thyroid Assoc. 2023;33:682\u201390. https:\/\/doi.org\/10.1089\/thy.2022.0704.","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"1736_CR105","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1111\/cas.15465","volume":"113","author":"K Ohno","year":"2022","unstructured":"Ohno K, Shibata T, Ito K-I. Epidermal growth factor receptor activation confers resistance to lenvatinib in thyroid cancer cells. Cancer Sci. 2022;113:3193\u2013210. https:\/\/doi.org\/10.1111\/cas.15465.","journal-title":"Cancer Sci"},{"key":"1736_CR106","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","volume":"8","author":"O Casanovas","year":"2005","unstructured":"Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005;8:299\u2013309. https:\/\/doi.org\/10.1016\/j.ccr.2005.09.005.","journal-title":"Cancer Cell"},{"key":"1736_CR107","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/aps.2017.5","volume":"38","author":"Y-J Zhu","year":"2017","unstructured":"Zhu Y-J, Zheng B, Wang H-Y, Chen L. New knowledge of the mechanisms of Sorafenib resistance in liver cancer. Acta Pharmacol Sin. 2017;38:614\u201322. https:\/\/doi.org\/10.1038\/aps.2017.5.","journal-title":"Acta Pharmacol Sin"},{"key":"1736_CR108","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.1111\/jcmm.14365","volume":"23","author":"Z Wang","year":"2019","unstructured":"Wang Z, Dai J, Yan J, Zhang Y, Yin Z. Targeting EZH2 as a novel therapeutic strategy for sorafenib-resistant thyroid carcinoma. J Cell Mol Med. 2019;23:4770\u20138. https:\/\/doi.org\/10.1111\/jcmm.14365.","journal-title":"J Cell Mol Med"},{"key":"1736_CR109","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00937-8","volume":"13","author":"R Duan","year":"2020","unstructured":"Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020;13:104. https:\/\/doi.org\/10.1186\/s13045-020-00937-8.","journal-title":"J Hematol Oncol"},{"key":"1736_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21010237","volume":"21","author":"HY Khan","year":"2019","unstructured":"Khan HY, Ge J, Nagasaka M, Aboukameel A, Mpilla G, Muqbil I, et al. Targeting XPO1 and PAK4 in 8505C anaplastic thyroid cancer cells: putative implications for overcoming lenvatinib therapy resistance. Int J Mol Sci. 2019;21:237. https:\/\/doi.org\/10.3390\/ijms21010237.","journal-title":"Int J Mol Sci"},{"key":"1736_CR111","doi-asserted-by":"publisher","first-page":"R173","DOI":"10.1530\/ERC-22-0129","volume":"29","author":"M-C Hofmann","year":"2022","unstructured":"Hofmann M-C, Kunnimalaiyaan M, Wang JR, Busaidy NL, Sherman SI, Lai SY, et al. Molecular mechanisms of resistance to kinase inhibitors and redifferentiation in thyroid cancers. Endocr Relat Cancer. 2022;29:R173\u201390. https:\/\/doi.org\/10.1530\/ERC-22-0129.","journal-title":"Endocr Relat Cancer"},{"key":"1736_CR112","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cancergen.2022.03.002","volume":"264","author":"G Harada","year":"2022","unstructured":"Harada G, Drilon A. TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults. Cancer Genet. 2022;264:33\u20139. https:\/\/doi.org\/10.1016\/j.cancergen.2022.03.002.","journal-title":"Cancer Genet"},{"key":"1736_CR113","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1038\/s41591-019-0542-z","volume":"25","author":"E Cocco","year":"2019","unstructured":"Cocco E, Schram AM, Kulick A, Misale S, Won HH, Yaeger R, et al. Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nat Med. 2019;25:1422\u20137. https:\/\/doi.org\/10.1038\/s41591-019-0542-z.","journal-title":"Nat Med"},{"key":"1736_CR114","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.592202","volume":"10","author":"A Porter","year":"2020","unstructured":"Porter A, Wong DJ. Perspectives on the treatment of advanced thyroid cancer: approved therapies, resistance mechanisms, and future directions. Front Oncol. 2020;10:592202. https:\/\/doi.org\/10.3389\/fonc.2020.592202.","journal-title":"Front Oncol"},{"key":"1736_CR115","doi-asserted-by":"publisher","first-page":"42445","DOI":"10.18632\/oncotarget.6442","volume":"6","author":"M Duquette","year":"2015","unstructured":"Duquette M, Sadow PM, Husain A, Sims JN, Antonello ZA, Fischer AH, et al. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model. Oncotarget. 2015;6:42445\u201367. https:\/\/doi.org\/10.18632\/oncotarget.6442.","journal-title":"Oncotarget"},{"key":"1736_CR116","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194950","volume":"13","author":"R Bagheri-Yarmand","year":"2021","unstructured":"Bagheri-Yarmand R, Busaidy NL, McBeath E, Danysh BP, Evans KW, Moss TJ, et al. RAC1 alterations induce acquired dabrafenib resistance in association with anaplastic transformation in a papillary thyroid cancer patient. Cancers. 2021;13:4950. https:\/\/doi.org\/10.3390\/cancers13194950.","journal-title":"Cancers"},{"key":"1736_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1176731","volume":"14","author":"S Hamidi","year":"2023","unstructured":"Hamidi S, Hofmann M-C, Iyer PC, Cabanillas ME, Hu MI, Busaidy NL, et al. Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance. Front Endocrinol. 2023;14:1176731. https:\/\/doi.org\/10.3389\/fendo.2023.1176731.","journal-title":"Front Endocrinol"},{"key":"1736_CR118","doi-asserted-by":"publisher","first-page":"15250","DOI":"10.18632\/oncotarget.3888","volume":"6","author":"A Delmas","year":"2015","unstructured":"Delmas A, Cherier J, Pohorecka M, Medale-Giamarchi C, Meyer N, Casanova A, et al. The c-Jun\/RHOB\/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors. Oncotarget. 2015;6:15250\u201364. https:\/\/doi.org\/10.18632\/oncotarget.3888.","journal-title":"Oncotarget"},{"key":"1736_CR119","doi-asserted-by":"publisher","first-page":"30907","DOI":"10.18632\/oncotarget.9023","volume":"7","author":"BP Danysh","year":"2016","unstructured":"Danysh BP, Rieger EY, Sinha DK, Evers CV, Cote GJ, Cabanillas ME, et al. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Oncotarget. 2016;7:30907\u201323. https:\/\/doi.org\/10.18632\/oncotarget.9023.","journal-title":"Oncotarget"},{"key":"1736_CR120","doi-asserted-by":"publisher","first-page":"409","DOI":"10.6004\/jnccn.2019.7292","volume":"17","author":"DH Owen","year":"2019","unstructured":"Owen DH, Konda B, Sipos J, Liu T, Webb A, Ringel MD, et al. KRAS G12V mutation in acquired resistance to combined BRAF and MEK inhibition in papillary thyroid cancer. J Natl Compr Cancer Netw JNCCN. 2019;17:409\u201313. https:\/\/doi.org\/10.6004\/jnccn.2019.7292.","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"1736_CR121","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","volume":"15","author":"BJ Solomon","year":"2020","unstructured":"Solomon BJ, Tan L, Lin JJ, Wong SQ, Hollizeck S, Ebata K, et al. RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies. J Thorac Oncol. 2020;15:541\u20139. https:\/\/doi.org\/10.1016\/j.jtho.2020.01.006.","journal-title":"J Thorac Oncol"},{"key":"1736_CR122","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-24-0224","volume":"32","author":"RJ Clifton-Bligh","year":"2025","unstructured":"Clifton-Bligh RJ. Mechanisms of resistance to RET-directed therapies. Endocr Relat Cancer. 2025;32:e240224. https:\/\/doi.org\/10.1530\/ERC-24-0224.","journal-title":"Endocr Relat Cancer"},{"key":"1736_CR123","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00278","volume":"5","author":"D Hanf","year":"2021","unstructured":"Hanf D, Heining C, Laaber K, Nebelung H, Uhrig S, Hutter B, et al. Response to cabozantinib following acquired entrectinib resistance in a patient with ETV6-NTRK3 fusion-positive carcinoma harboring the NTRK3 G623R solvent-front mutation. JCO Precis Oncol. 2021;5:PO.20.00278. https:\/\/doi.org\/10.1200\/PO.20.00278.","journal-title":"JCO Precis Oncol"},{"key":"1736_CR124","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1406470.","journal-title":"N Engl J Med"},{"key":"1736_CR125","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","volume":"389","author":"J Hadoux","year":"2023","unstructured":"Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, et al. Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer. N Engl J Med. 2023;389:1851\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2309719.","journal-title":"N Engl J Med"},{"key":"1736_CR126","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1089\/thy.2014.0134","volume":"24","author":"TE Angell","year":"2014","unstructured":"Angell TE, Lechner MG, Jang JK, Correa AJ, LoPresti JS, Epstein AL. BRAFV600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid. 2014;24:1385\u201393. https:\/\/doi.org\/10.1089\/thy.2014.0134.","journal-title":"Thyroid"},{"key":"1736_CR127","doi-asserted-by":"publisher","first-page":"6512","DOI":"10.1200\/JCO.2020.38.15_suppl.6512","volume":"38","author":"B Haugen","year":"2020","unstructured":"Haugen B, French J, Worden FP, Konda B, Sherman EJ, Dadu R, et al. Lenvatinib plus pembrolizumab combination therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC): results of a multicenter phase II international thyroid oncology group trial. J Clin Oncol Wolters Kluwer. 2020;38:6512\u20136512. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.6512.","journal-title":"J Clin Oncol Wolters Kluwer"},{"key":"1736_CR128","doi-asserted-by":"publisher","first-page":"viii646","DOI":"10.1093\/annonc\/mdy302.004","volume":"29","author":"C Dierks","year":"2018","unstructured":"Dierks C, Miething C, Thomusch O, von Bubnoff N, Duyster J. Lenvatinib and pembrolizumab as save and effective combination treatment in 8 patients with metastasized anaplastic (ATC) or poorly differentiated thyroid carcinoma (PDTC). Ann Oncol Elsevier. 2018;29:viii646. https:\/\/doi.org\/10.1093\/annonc\/mdy302.004.","journal-title":"Ann Oncol Elsevier"},{"key":"1736_CR129","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0378-y","volume":"6","author":"PC Iyer","year":"2018","unstructured":"Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer. 2018;6:68. https:\/\/doi.org\/10.1186\/s40425-018-0378-y.","journal-title":"J Immunother Cancer"},{"key":"1736_CR130","doi-asserted-by":"publisher","first-page":"5362","DOI":"10.3390\/cancers14215362","volume":"14","author":"M Faria","year":"2022","unstructured":"Faria M, Vareda J, Miranda M, Bugalho MJ, Silva AL, Matos P. Adherens junction integrity is a critical determinant of sodium iodide symporter residency at the plasma membrane of thyroid cells. Cancers. 2022;14:5362. https:\/\/doi.org\/10.3390\/cancers14215362.","journal-title":"Cancers"},{"key":"1736_CR131","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1210\/jcem.85.8.6732","volume":"85","author":"J Kurebayashi","year":"2000","unstructured":"Kurebayashi J, Tanaka K, Otsuki T, Moriya T, Kunisue H, Uno M, et al. All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J Clin Endocrinol Metab. 2000;85:2889\u201396. https:\/\/doi.org\/10.1210\/jcem.85.8.6732.","journal-title":"J Clin Endocrinol Metab"},{"key":"1736_CR132","first-page":"2316","volume":"63","author":"M Xing","year":"2003","unstructured":"Xing M, Usadel H, Cohen Y, Tokumaru Y, Guo Z, Westra WB, et al. Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene Silencing. Cancer Res. 2003;63:2316\u201321.","journal-title":"Cancer Res"},{"key":"1736_CR133","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1158\/0008-5472.CAN-19-1957","volume":"80","author":"A Fletcher","year":"2020","unstructured":"Fletcher A, Read ML, Thornton CEM, Larner DP, Poole VL, Brookes K, et al. Targeting novel sodium iodide symporter interactors ADP-ribosylation factor 4 and valosin-containing protein enhances radioiodine uptake. Cancer Res. 2020;80:102\u201315. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-1957.","journal-title":"Cancer Res"},{"key":"1736_CR134","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S2213-8587(25)00064-6","volume":"13","author":"S Leboulleux","year":"2025","unstructured":"Leboulleux S, Boucai L, Busaidy N, Durante C, Fagin JA, Fazeli S, et al. Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement. Lancet Diabetes Endocrinol. 2025;13:516\u201327. https:\/\/doi.org\/10.1016\/S2213-8587(25)00064-6.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1736_CR135","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1089\/thy.2021.0524","volume":"32","author":"L Groussin","year":"2022","unstructured":"Groussin L, Theodon H, Bessiene L, Bricaire L, Bonnet-Serrano F, Cochand-Priollet B, et al. Redifferentiating effect of larotrectinib in NTRK-rearranged advanced radioactive-iodine refractory thyroid cancer. Thyroid. 2022;32:594\u20138. https:\/\/doi.org\/10.1089\/thy.2021.0524.","journal-title":"Thyroid"},{"key":"1736_CR136","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1089\/thy.2021.0144","volume":"31","author":"L Groussin","year":"2021","unstructured":"Groussin L, Bessiene L, Arrondeau J, Garinet S, Cochand-Priollet B, Lupo A, et al. Letter to the editor: selpercatinib-enhanced radioiodine uptake in RET-rearranged thyroid cancer. Thyroid. 2021;31:1603\u20134. https:\/\/doi.org\/10.1089\/thy.2021.0144.","journal-title":"Thyroid"},{"key":"1736_CR137","doi-asserted-by":"publisher","first-page":"80","DOI":"10.5306\/wjco.v2.i2.80","volume":"2","author":"F Broekman","year":"2011","unstructured":"Broekman F, Giovannetti E, Peters GJ. Tyrosine kinase inhibitors: multi-targeted or single-targeted? World J Clin Oncol. 2011;2:80\u201393. https:\/\/doi.org\/10.5306\/wjco.v2.i2.80.","journal-title":"World J Clin Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01736-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01736-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01736-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T15:54:05Z","timestamp":1770306845000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01736-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":137,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1736"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01736-z","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9"}}